Eligo Bioscience Raises $30 Million To Write a...
Press Release Service
Dec. 5, 2023
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Viacyte
Main focus: Stem cell engineering for treatment of diabetes
Company stage: Clinical
Diseases: Type 1 and 2 diabetes
Genome editing tool: CRISPR-Cas9
Funding stage: Private
Location: San Diego, CA, USA
Website: https://viacyte.com/
Pipeline: https://viacyte.com/pipeline/
Partners: CRISPR Therapeutics
Viacyte is developing engineered stem cells in order to treat diabetes. The company has an ongoing collaboration with CRISPR Therapeutics, for which the companies seek to develop a next generation stem cell product for all type 1 diabetes and insulin-requiring type 2 diabetes patients. The programme is currently in a research phase.
